Search

Your search keyword '"Navarro Martin, M."' showing total 13 results
Start Over Author "Navarro Martin, M."
13 results on '"Navarro Martin, M."'

1. 1163P Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)

Author

Terán Brage, E., Reguera Puertas, P., Campaña-Díaz, E., Navarro Martín, M., Garcia Talavera, P., Rama Alonso, S., López Gutiérrez, Á., Roldan Ruiz, J., Garijo Martínez, M.D.C., Morchón Araujo, D., Posado-Domínguez, L., Redondo González, J.C., Díaz Sánchez, P., Pablo Martín, E., Felix, L.C., Lozano Mejorada, R., and Fonseca Sánchez, E.

Published
2024
Full Text
View/download PDF

4. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial

Author

Salgado, M.A.V., primary, Sepulveda Sanchez, J.M., additional, del barco, S., additional, Pineda, E., additional, Fuster, J., additional, Navarro Martin, M., additional, Herrero Ibañez, A., additional, Alonso, M., additional, Perez, J., additional, Mesia, C., additional, Munoz-Langa, J., additional, de las Penas Bataller, R., additional, Peralta, S., additional, Olier, C., additional, Pérez-Segura, P., additional, Estival, A., additional, Carrato, C., additional, Saez, C., additional, Gil, M.J., additional, and Balana, C., additional

Published
2019
Full Text
View/download PDF

5. Spanish survey of treatment recommendations for elderly patients with glioblastoma

Author

Vaz Salgado, M Á, primary, Rodríguez Sánchez, Á, additional, Fernandez Perez, I., additional, Quintanar, T., additional, Navarro Martin, M., additional, Vieito Villar, M., additional, Cano, J.M., additional, Gonzalez, S., additional, Ros, S., additional, Herrero Ibañez, A., additional, Ivars, M.A., additional, Lloret, M., additional, Alonso, M., additional, Moya, I., additional, Luque, R., additional, Benavides, M., additional, Gutiérrez Toribio, M., additional, García-Gómez, J., additional, Esteban Villarrubia, J., additional, and Torres Jimenez, J., additional

Published
2019
Full Text
View/download PDF

6. 1924P Diagnostic demographics of radioiodine-refractory differentiated thyroid cancer (RR-DTC) and usage patterns of local and systemic therapies (ERUDIT study)

Author

López, C., Santos, R.J., Llanos Muñoz, M., Vallejo, J.A., Navarro González, E., Aller Pardo, J., Pubul Núñez, V., Sambo Salas, M., Guadalix Iglesias, S., Crespo, G., Zafon, C., González Blanco, C., Segura Huerta, Á.A., Navarro Martín, M., Santamaría Sandi, J., Gajate Borau, P., Valdivia, J., Gómez Balaguer, M., Orcajo Rincon, L., and Rodríguez-Villanueva, J.

Published
2020
Full Text
View/download PDF

12. SENSING DEVELOPMENT OF A SOYBEAN CANOPY UNDER P OR K NUTRITIONAL STRESS

Author

Navarro, Martin M.

Subjects
NDVI, soybean, phosphorus, potassium, proximal sensing, Plant Sciences
Abstract

The normalized difference vegetative index (NDVI) has been correlated with physiological plant parameters and used to evaluate plant growth. There is little information about the use of this technique to detect soybean nutrient deficiencies. The objective of this work was to determine the ability of the NDVI sensor to detect P and K deficiencies, and grain yield reduction, in soybean. During 2010 and 2011, NDVI measurements were made on a soybean field trial site known to exhibit yield responses to both P and K nutrition. Four replicates of 8 levels each of P and K nutrition were evaluated. The NDVI measurements were made with an active proximal sensor held parallel to the soil surface every seven days after V2, and until R2. At each measurement a mean NDVI value was found for each plot. Phosphorus deficiency was detected with the first NDVI measurement. Potassium deficiency was first detected just after V4. Differences in NDVI values due to P or K nutrition increased with continued crop development. There were significant R1 leaf composition and grain yield responses to improved P or K nutrition. The active proximal sensor was able to detect soybean growth differences due to P or K deficiencies in soybean.

Published
2012

13. Large cell neuroendocrine carcinoma of the lung with atypical evolution and a remarkable response to lutetium Lu 177 dotatate.

Author

Escala Cornejo RA, García-Talavera P, Navarro Martin M, Pérez López B, García Muñoz M, Tamayo Alonso MP, and Cruz Hernández JJ

Subjects
Humans, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Grading, Neuroendocrine Tumors pathology, Octreotide therapeutic use, Quality of Life, Treatment Outcome, Lung Neoplasms radiotherapy, Neuroendocrine Tumors radiotherapy, Octreotide analogs & derivatives, Organometallic Compounds therapeutic use
Abstract

Large cell neuroendocrine carcinoma of the lung (LCNEC) is a high-grade, poorly differentiated tumor that typically does not express somatostatin receptors. Thus, it does not benefit from treatment with somatostatin analogs and peptide receptor radionuclide therapy (PRRT). The current study objective was to demonstrate that treatment with PRRT may be a valid option in neuroendocrine carcinomas with high expression of somatostatin receptors. This is a case report of a 58-year-old man who was diagnosed with LCNEC and received chemotherapy treatment with little benefit. Extensive hepatic and bone metastasis was detected on 111 In-pentetreotide scintigraphy following high uptake of the radionuclide by the tumors. The patient benefitted from neuroendocrine treatment initially and from lutetium Lu 177 dotatate subsequently. A significant clinical and radiological response was observed, along with an improvement in quality of life. The use of PRRT is a valid alternative to chemotherapy in patients with LCNEC involving the expression of somatostin receptors.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results